Global t-cell therapy market likely to propelling due to the rise in prevalence of cancer across the globe
Global T-cell therapy market estimated to grow with a CAGR of over 12.4% during the forecast period, 2020-2027. It is primarily attributed to the rising prevalence of cancer across the world and an increase in cancer research & development across the globe. According to WHO, around 70% of deaths from cancer occur in low-and middle-income countries, and also WHO stated that, by 2030, approximately 10 to 11 million cases of cancers would be diagnosed each year in low-and middle-income countries. Additionally, the increasing network of diverse CAR-T/TCR developers with their products offering will accelerate the t-cell therapy market size in the forecast timeline. In 2019, the U.S. Center for Medical Insurance and Medicaid Services (CMS) approved for medical insurance for T-cell therapy. Moreover, technological advancements in developments and processes in CAR T-cell therapy for solid tumors and the approvals and clinical success of Kymriah and Yescarta will fuel the robust growth of the t-cell therapy industry in the projected time. T-cell therapy uses immune cells extracted from the patient's blood to recompile them to identify and attack specific proteins found in brain tumors, and then re-import the immune cells into the patient's body system.
Furthermore, the surge in the number of patients presenting a failure response to alternative therapies coupled with the increasing occurrence of cancer cases across the globe will spur the global T-cell therapy market share in the future periods. Also, high cancer cases around the world projected to raise the demand for a reliable and effective therapeutic treatment approach that will augment the global t-cell therapy industry in the next few years.
Therapy Type Overview in the Global T-cell therapy Market
Based on therapy type, the global t-cell therapy market classified into CAR T-Cell Therapy, T Cell Receptor (TCR), and Tumor-Infiltrating Lymphocytes. The CAR T-Cell Therapy segment will be the fastest-growing segment in the forecast period. It is attributable to the effectiveness of CAR-T cell therapy, such that it has higher efficacy than other therapies currently available on the market for the treatment of cancer. The ability of CAR to integrate onto the surface of T cells, primarily when delivered by monoclonal antibodies, promotes T cells to more easily penetrate cancer-causing cells of patients.
T Cell Receptor (TCR) will grow at a significant rate in the forecast period. It is due to the T cell receptor (TCR) used for leukemia or other tumor cells.
Modality Overview in the Global T-cell therapy market
Based on modality, the global t-cell therapy market bifurcated into Research and Commercialized. The Commercialized will be the fastest-growing segment in the forecast period owing to the investment by start-up companies in treatment technologies of cancer diseases and approval of cell therapy by the USA and European Union.
Indication Overview in the Global T-cell therapy Market
Based on the indication, the global t-cell therapy market bifurcates into Hematologic Malignancies (Lymphoma, Leukemia, and Myeloma) and Solid Tumors (Melanoma, Brain & Central Nervous System, Liver cancer and others). The Hematologic Malignancies segment accounted for a larger market share in 2019 and projected to lead the market by 2027. It is due to t-cell therapy demand for the treatment of Lymphoma, Leukemia, and Myeloma.
Solid Tumors will grow with a lucrative rate during the analysis timespan owing to advanced t-cell therapy techniques find a way for the treatment of Melanoma, Brain & Central Nervous System, and Liver cancer.
Regional Overview in the Global T-cell therapy Market
By geography, the Global T-cell therapy Market segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America accounted for maximum revenue share in 2019, owing to the presence of keys players in these regions, the large number of research institute presence coupled with the approval of t-cell therapy in the U.S. and Canada by FDA.
Global T-cell therapy Market: Competitive Landscape
Companies such as Novartis AG, Gilead Sciences, bluebird bio, TCR2 Therapeutics Inc., Sorrento Therapeutics, Kite Pharma, Merck KGaA, Pfizer, Amgen, Celgene Corporation and Fate Therapeutics are the key players in the Global T-Cell Therapy Market.
Global T-cell Therapy Market Report Content 1. Research Strategic Development 1.1. Market Modelling 1.2. Product Analysis 1.3. Market Trend and Economic Factors Analysis 1.4. Market Segmental Analysis 1.5. Geographical Mapping 1.6. Country Wise Segregation 2. Research Methodology 2.1. Identification of Target Market 2.2. Data Acquisition 2.3. Refining of Data/ Data Transformations 2.4. Data Validation through Primary Techniques 2.5. Exploratory Data Analysis 2.6. Graphical Techniques/Analysis 2.7. Quantitative Techniques/Analysis 2.8. Visual Result/Presentation 3. Executive Summary 4. Market Insights 4.1. Economic Factor Analysis 4.1.1. Drivers 4.1.2. Trends 4.1.3. Opportunities 4.1.4. Challenges 4.2. Technological Landscape 4.3. Competitors & Product Analysis 4.4. Regulatory Framework 4.5. Company market share analysis, 2019 4.6. Porter's Five forces analysis 4.7. New Investment Analysis 4.8. PESTEL Analysis 5. Global T-cell Therapy Market Overview 5.1. Market Size & Forecast, 2016-2027 5.1.1. Demand 5.1.1.1. By Value (USD Million) 5.2. Market Share & Forecast, 2016-2027 5.2.1. By Modality 5.2.1.1. Research 5.2.1.2. Commercialized 5.2.2. By Therapy Type 5.2.2.1. CAR T-Cell Therapy 5.2.2.2. T Cell Receptor (TCR) 5.2.2.3. Tumor Infiltrating Lymphocytes 5.2.3. By Indication 5.2.3.1. Hematologic Malignancies 5.2.3.1.1. Lymphoma 5.2.3.1.2. Leukemia 5.2.3.1.3. Myeloma 5.2.3.2. Solid Tumors 5.2.3.2.1. Melanoma 5.2.3.2.2. Brain & Central Nervous System 5.2.3.2.3. Liver cancer 5.2.3.2.4. Others 5.2.4. By Region 5.2.4.1. North America 5.2.4.2. Europe 5.2.4.3. Asia Pacific 5.2.4.4. South America 5.2.4.5. Middle East & Africa 6. North America T-cell Therapy Market Overview 6.1. North America T-cell Therapy Market Size & Forecast, 2016-2027 6.1.1. Demand 6.1.1.1. By Value (USD Million) 6.2. North America T-cell Therapy Market Share & Forecast, 2016-2027 6.2.1. By Modality 6.2.1.1. Research 6.2.1.2. Commercialized 6.2.2. By Therapy Type 6.2.2.1. CAR T-Cell Therapy 6.2.2.2. T Cell Receptor (TCR) 6.2.2.3. Tumor Infiltrating Lymphocytes 6.2.3. By Indication 6.2.3.1. Hematologic Malignancies 6.2.3.1.1. Lymphoma 6.2.3.1.2. Leukemia 6.2.3.1.3. Myeloma 6.2.3.2. Solid Tumors 6.2.3.2.1. Melanoma 6.2.3.2.2. Brain & Central Nervous System 6.2.3.2.3. Liver cancer 6.2.3.2.4. Others 6.2.4. By Country 6.2.4.1. US 6.2.4.2. Canada 6.2.4.3. Mexico 6.2.5. Company Market Share (Top 3-5) 6.2.6. Economic Impact Study on North America T-cell Therapy Market 7. Europe T-cell Therapy Market Overview 7.1. Europe T-cell Therapy Market Size & Forecast, 2016-2027 7.1.1. Demand 7.1.1.1. By Value (USD Million) 7.2. Europe T-cell Therapy Market Share & Forecast, 2016-2027 7.2.1. By Modality 7.2.1.1. Research 7.2.1.2. Commercialized 7.2.2. By Therapy Type 7.2.2.1. CAR T-Cell Therapy 7.2.2.2. T Cell Receptor (TCR) 7.2.2.3. Tumor Infiltrating Lymphocytes 7.2.3. By Indication 7.2.3.1. Hematologic Malignancies 7.2.3.1.1. Lymphoma 7.2.3.1.2. Leukemia 7.2.3.1.3. Myeloma 7.2.3.2. Solid Tumors 7.2.3.2.1. Melanoma 7.2.3.2.2. Brain & Central Nervous System 7.2.3.2.3. Liver cancer 7.2.3.2.4. Others 7.2.4. By Country 7.2.4.1. Germany 7.2.4.2. UK 7.2.4.3. France 7.2.4.4. Italy 7.2.4.5. Rest of Europe 7.2.5. Company Market Share (Top 3-5) 7.2.6. Economic Impact Study on Europe T-cell Therapy Market 8. Asia Pacific T-cell Therapy Market Overview 8.1. Asia Pacific T-cell Therapy Market Size & Forecast, 2016-2027 8.1.1. Demand 8.1.1.1. By Value (USD Million) 8.2. Asia Pacific T-cell Therapy Market Share & Forecast, 2016-2027 8.2.1. By Modality 8.2.1.1. Research 8.2.1.2. Commercialized 8.2.2. By Therapy Type 8.2.2.1. CAR T-Cell Therapy 8.2.2.2. T Cell Receptor (TCR) 8.2.2.3. Tumor Infiltrating Lymphocytes 8.2.3. By Indication 8.2.3.1. Hematologic Malignancies 8.2.3.1.1. Lymphoma 8.2.3.1.2. Leukemia 8.2.3.1.3. Myeloma 8.2.3.2. Solid Tumors 8.2.3.2.1. Melanoma 8.2.3.2.2. Brain & Central Nervous System 8.2.3.2.3. Liver cancer 8.2.3.2.4. Others 8.2.4. By Country 8.2.4.1. China 8.2.4.2. India 8.2.4.3. Japan 8.2.4.4. Australia 8.2.4.5. Rest of Asia Pacific 8.2.5. Company Market Share (Top 3-5) 8.2.6. Economic Impact Study on Asia Pacific T-cell Therapy Market 9. South America T-cell Therapy Market Overview 9.1. South America T-cell Therapy Market Size & Forecast, 2016-2027 9.1.1. Demand 9.1.1.1. By Value (USD Million) 9.2. South America T-cell Therapy Market Share & Forecast, 2016-2027 9.2.1. By Modality 9.2.1.1. Research 9.2.1.2. Commercialized 9.2.2. By Therapy Type 9.2.2.1. CAR T-Cell Therapy 9.2.2.2. T Cell Receptor (TCR) 9.2.2.3. Tumor Infiltrating Lymphocytes 9.2.3. By Indication 9.2.3.1. Hematologic Malignancies 9.2.3.1.1. Lymphoma 9.2.3.1.2. Leukemia 9.2.3.1.3. Myeloma 9.2.3.2. Solid Tumors 9.2.3.2.1. Melanoma 9.2.3.2.2. Brain & Central Nervous System 9.2.3.2.3. Liver cancer 9.2.3.2.4. Others 9.2.4. By Country 9.2.4.1. Brazil 9.2.4.2. Argentina 9.2.4.3. Rest of South America 9.2.5. Company Market Share (Top 3-5) 9.2.6. Economic Impact Study on South America T-cell Therapy Market 10. Middle East & Africa T-cell Therapy Market Overview 10.1. Middle East & Africa T-cell Therapy Market Size & Forecast, 2016-2027 10.1.1. Demand 10.1.1.1. By Value (USD Million) 10.2. Middle East & Africa T-cell Therapy Market Share & Forecast, 2016-2027 10.2.1. By Modality 10.2.1.1. Research 10.2.1.2. Commercialized 10.2.2. By Therapy Type 10.2.2.1. CAR T-Cell Therapy 10.2.2.2. T Cell Receptor (TCR) 10.2.2.3. Tumor Infiltrating Lymphocytes 10.2.3. By Indication 10.2.3.1. Hematologic Malignancies 10.2.3.1.1. Lymphoma 10.2.3.1.2. Leukemia 10.2.3.1.3. Myeloma 10.2.3.2. Solid Tumors 10.2.3.2.1. Melanoma 10.2.3.2.2. Brain & Central Nervous System 10.2.3.2.3. Liver cancer 10.2.3.2.4. Others 10.2.4. By Country 10.2.4.1. Saudi Arabia 10.2.4.2. UAE 10.2.4.3. South Africa 10.2.4.4. Rest of Middle East & Africa 10.2.5. Company Market Share (Top 3-5) 10.2.6. Economic Impact Study on Middle East & Africa T-cell Therapy Market 11. Competitor Analysis 11.1. Company Description 11.2. Financial Analysis 11.3. Key Products 11.4. Key Management Personnel 11.5. Contact Address 11.6. SWOT Analysis 11.7. Company Profile 11.7.1. Novartis AG 11.7.2. Gilead Sciences 11.7.3. bluebird bio 11.7.4. TCR2 Therapeutics Inc. 11.7.5. Sorrento Therapeutics 11.7.6. Kite Pharma 11.7.7. Merck KGaA 11.7.8. Pfizer 11.7.9. Amgen 11.7.10. Celgene Corporation 11.7.11. Fate Therapeutics 11.7.12. Other Prominent Players
| Price : US$ 3500 | Date : Nov 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 80 |
| Price : US$ 3500 | Date : Nov 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 142 |
| Price : US$ 3500 | Date : Nov 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 119 |
| Price : US$ 3500 | Date : Nov 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 139 |
| Price : US$ 3500 | Date : Nov 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 116 |
We will be happy to help you find what you need. Please call us or write to us:
Want us to send you latest updates of the current trends, insights, and more, signup to our newsletter (for alerts, special offers, and discounts).
This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection
Request Sample 
Request Discount 
Inquire Before Buy
